Parul S. Patel, M.D., Scientist; Transplant Nephrologist at CPMC

California Pacific CURRENTS: The online journal of CPMC Research Institute

Leading new advances in the treatment of kidney disease; improving outcomes after kidney transplantation

Research Overview

  • A member of CPMC's kidney transplant team, Dr. Patel is a leading expert in the management of kidney disease. He is board certified in nephrology.
  • Dr. Patel investigates the immune response after kidney transplantation; continuous renal replacement therapies; and new strategies to promote graft success and limit acute organ rejection after kidney transplant.
  • He is a co-investigator of clinical trials assessing the safety and efficacy of novel therapies in kidney transplant patients.


Dr. Patel received his M.D. from Baylor College of Medicine in Houston, Texas. He completed residency training in internal medicine and fellowships in transplant medicine and nephrology at Baylor College of Medicine and at Beth Israel Deaconess Medical Center in Boston.  He was previously on faculty as an Assistant Professor in medicine and nephrology at Baylor College of Medicine and Boston University Medical Center.


Publication Search


Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR, Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR, Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV

Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S, Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer

Trezza C, Ford SL, Gould E, Lou Y, Huang C, Ritter JM, Buchanan AM, Spreen W, Patel P, Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol

Parul S. Patel, M.D., Scientist; Transplant Nephrologist at CPMC
Primary Research Interests
  • Nephrology
  • Kidney transplantation